Newsletters and Deep Dive digital magazine
The FDA has approved Eli Lilly’s Emgality (galcanezumab-gnlm) for the treatment of episodic cluster headache in adults, giving the calcitonin gene-related peptide (CGRP) antibody a key poin
Eli Lilly has a battle on its hands in the migraine prevention category with third-to-market CGRP inhibitor Emgality but could get a leg-up with an indication in episodic cluster headache.<
FDA to make decision on Amgen drug tomorrow
Drug is first new echinocandin to be approved for marketing in the US in more than a decade.
An inside guide to unlocking clinical research in the UK